Endovascular Aneurysm Repair Market Size, Share, Growth, Trends, and Global Industry Analysis: By Indication (Abdominal aortic aneurysm and Thoracic aortic aneurysm), By Site (Infrarenal and Pararenal), By Anatomy (Traditional and complex), By Products (Percutaneous EVAR, Fenestrated EVAR, Aortic stents & TAA grafts, and others), and Region Forecast 2020-2031

Endovascular Aneurysm Repair Market size was valued at US$ 3.4 billion in 2024 and is expected to reach US$ 4.9 billion by 2031, growing at a significant CAGR of 5.1% from 2025-2031. Endovascular aneurysm repair (EVAR) refers to the medical field dedicated to treating aortic aneurysms including abdominal aortic aneurysm (AAA) and thoracic aortic aneurysm (TAC) using minimally invasive endovascular techniques. An aortic aneurysm develops when there is a bulging or weakening in the wall of the aorta, the principal artery from the heart, which can result in potentially fatal internal bleeding when ruptured or obstruct the flow of blood to numerous organs. EVAR is a cutting-edge procedure that employs tiny punctures and sophisticated instruments to repair aortic aneurysms. It has various benefits over traditional open surgery, including fewer traumas during operation, shorter hospital stays, and speedier recovery times. The foremost driver of the endovascular aneurysm repair (EVAR) market is the aging population and the rising prevalence of cardiovascular diseases, including aortic aneurysms. 

According to a research study, epidemiological studies of AAA have revealed an increasing incidence that ranges from 4.2% to 11% per year throughout the world with an overall mortality rate of 80% in the case of rupture. Moreover, advancements in endovascular technology and techniques have made the procedure safer, more precise, and less invasive, leading to increased patient acceptance and adoption of endovascular aneurysm repair systems. Furthermore, rising demand for minimally invasive procedures and emerging healthcare systems presents significant opportunities to further accelerate the growth of the market. However, the growth of the market is restrained by the high cost of devices and associated procedures. Key market players are involved in the development of innovative endovascular aneurysm repair system which is shaping the landscape of endovascular treatment for aortic aneurysms. For instance, in October 2019, Medtronic plc announced the approval of Shonin from the Ministry of Health, Labour and Welfare and the launch of the Valiant Navion thoracic stent graft system for the minimally invasive repair of thoracic descending aortic aneurysms (TAA) and complicated type B aortic dissections (TBAD).

Key Developments

• In Sept-2022, Getinge announced a partnership with Medtronic for the manufacturing of Radiant covered stent, the first covered stent developed for chimney endovascular aneurysm repair (ChEVAR).
• In November 2018, Cordis, a Cardinal Health company announced the approval of an ultra-low profile and flexible endovascular aneurysm repair (EVAR) system, INCRAFT AAA Stent Graft System from FDA to treat infrarenal abdominal aortic aneurysms (AAA).
• In May 2020, Terumo Aortic received FDA approval for the TREO Abdominal Aortic Stent-Graft System for sale in the United States for the treatment of patients with abdominal aortic aneurysms (AAA).